Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Haemonetics (HAE)

Haemonetics Q4 GAAP loss of $0.44 per share on $77 million impairment; revenue up 4.8%

Mixed Impact 4 of 5 earnings Written later

Haemonetics reported fourth-quarter fiscal 2026 revenue of $346.4 million, up 4.8%, and adjusted earnings of $1.29 per diluted share, up 4.0%. A $77.2 million impairment of intangible assets tied to Attune Medical turned the quarter to a GAAP net loss of $20.1 million, or $(0.44) per share, and the company also issued fiscal 2027 guidance calling for reported revenue growth of 4% to 7%.

Key points

  • Q4 fiscal 2026 revenue of $346.4 million, up 4.8%; organic growth 4.5%, organic ex-CSL growth 8.6%
  • Q4 GAAP net loss of $20.1 million, or $(0.44) per share, versus net income of $58.0 million, or $1.17 per share, a year earlier
  • Fiscal 2026 revenue of $1.334 billion, down 2.0%; GAAP EPS $2.05 versus $3.31; adjusted EPS $4.96
  • Fiscal 2027 guidance: reported revenue growth 4% to 7%, organic growth 3% to 6%, adjusted operating margin expansion of 50 to 100 basis points

The filing

CompanyHaemonetics (HAE)
Form8-K, current report
Filed with the SECMay 7, 2026, 6:02 AM ET
Accession number0000313143-26-000031

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.